Docoh
Loading...

IPA ImmunoPrecise Antibodies

News

From Benzinga Pro
ImmunoPrecise Antibodies And ChemPartner Biologics Announce PolyTope TATX-03 Antibody Cocktail Manufacturing Collaboration
20 Dec 21
Biotech, General
IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ:IPA) (TSXV:IPA) and ChemPartner Biologics Co. Ltd. ("ChemPartner") today announced their global antibody manufacturing
ImmunoPrecise Antibodies Q2 Sales $4.70M
13 Dec 21
Earnings, News
ImmunoPrecise Antibodies (NASDAQ:IPA) reported $4.70 million in sales this quarter.
ImmunoPrecise Antibodies Says Polytope Reaches Multiple Milestones; Co Says Has Commenced Omicron Variant Analysis
30 Nov 21
News, FDA, Movers, Trading Ideas
Polytope™ Reaches Multiple Milestones and IPA Has Commenced Omicron Variant Analysis IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSXV:IPA) is providing an update on its
56 Biggest Movers From Friday
29 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
48 Stocks Moving In Friday's Mid-Day Session
26 Nov 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded higher amid concerns of a new COVID variant discovered in South Africa.
Immunoprecise Antibodies To Present At Benchmark's Discovery 1-On-1 Investor Conference On Dec. 2, 2021
24 Nov 21
News, Events
IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ:IPA) (TSXV:IPA) is presenting at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference. The conference

Press releases

From Benzinga Pro
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability
18 Jan 22
Press Releases
IPA Europe's Oss laboratories make a move to new Centre of Excellence facilities in Oss, Netherlands, with progressive environmental impact measures. IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA)
ImmunoPrecise Antibodies Announces Grant of Stock Options
17 Jan 22
Press Releases
IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ:IPA) (TSXV:IPA), a leader in full-service, therapeutic antibody discovery, today announced that on January 13, 2022 its board of directors approved the
ImmunoPrecise Antibodies Announces Grant of Stock Options
11 Jan 22
Press Releases
IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ:IPA) (TSXV:IPA), a leader in full-service, therapeutic antibody discovery, today announced that on January 7, 2022 its board of directors approved the grant
ImmunoPrecise Antibodies Announces Grant of Stock Options
3 Jan 22
Press Releases
IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ:IPA) (TSXV:IPA), a leader in full-service, therapeutic antibody discovery, today announced that its board of directors has approved the grant of 28,250
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration
20 Dec 21
Press Releases
IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ:IPA) (TSXV:IPA) and ChemPartner Biologics Co. Ltd. ("ChemPartner") today announced their global antibody manufacturing collaboration under which ChemPartner
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
13 Dec 21
Press Releases
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSXV:IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for second quarter fiscal year
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
7 Dec 21
Press Releases
The Company to host an earnings conference call via webcast on December 13, 2021 at the close of market IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSXV:IPA) a leader in
ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program
30 Nov 21
Press Releases
Polytope™ Reaches Multiple Milestones and IPA Has Commenced Omicron Variant Analysis IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSXV:IPA) is providing an update on its Polytope™
ImmunoPrecise to Present at the Benchmark Company's Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021
24 Nov 21
Press Releases
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSXV:IPA) is presenting at the Benchmark Company's Discovery One-on-One Virtual Video Investor Conference. The conference is being held on December
IPA Announces Resignation of Director
9 Nov 21
Press Releases
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSXV:IPA) announced today that Paul Andreola, a member of the Board of Directors of IPA, has resigned, effective immediately, from the Company's